Providers managing hyperphosphatemia in patients with CKD who are on dialysis may be challenged when it comes to diagnosis, treatment, and management. Learn about the pathophysiology, key diagnostic markers, and the latest in clinical trial data in this multispecialty faculty program.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Steven N. Fishbane, MD
Professor, Institute of Health System Science
Feinstein Institutes for Medical Research
Manhasset, NY
Dr. Fishbane has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: Ardelyx
Consulting fees: Ardelyx
Stuart M. Sprague, DO, FACP, FASN, FNKF
Director of Nephrology Research Division of Nephrology and Hypertension NorthShore University HealthSystem
Evanston, Il
Dr. Sprague has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research support: Ardelyx
Consulting fees: Ardelyx
Kathleen Hill Gallant, PhD, RD
Associate Professor
Director of Graduate Studies – Nutrition
University of Minnesota
Saint Paul, MN
Dr. Gallant has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Ownership interest: stock options with HelioGenomics as a benefit through spouse’s employer
Reviewers/Content Planners/Authors:
This activity has been designed to meet the educational needs of nephrologists and dieticians as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing hyperphosphatemia in patients with CKD on hemodialysis.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 credit nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1 contact hour/0.10 of pharmacy contact hours.
The Universal Activity Number for this program is JA0006235-0000-24-160-H01-P This learning activity knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 credit AAPA Category 1 CME credit(s). Approval is valid until January 10, 2026. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
This activity is supported by an independent educational grant from Ardelyx, Inc.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.”
Release Date:
Expiration Date:
